Exscientia

Exscientia Ltd. is a developer of artificial intelligence (AI)-driven drug discovery technology, aimed at addressing new drugs for complex disease areas. The company’s technology actively learns from previous experimental results, identifying and assimilating various subtle and complex compounds and formulations to balance potency, selectivity, and pharmacokinetic criteria, enabling pharmaceutical companies to leverage new opportunities for treating complex diseases where the target mechanisms are often unknown. Their knowledge-driven system provides better information than any individual researcher could obtain, capable of designing millions of novel compounds tailored to specific projects and pre-evaluating each compound to predict efficacy, selectivity, ADME, and other key criteria. From this, the best and most informative compounds are selected for synthesis and analysis.